Ritz peanut butter crackers recalled over labeling mistake
July 11 (UPI) -- A labeling mistake has led to a nationwide recall of four different types of Ritz peanut butter cracker sandwich cartons, federal health officials said.
Mondelēz Global LLC, the parent company of Ritz, is recalling the products because some packages containing peanut butter may be incorrectly labeled as cheese, the U.S. Food and Drug Administration said in a safety notice.
That mistake could put people with peanut allergies at risk of "serious or life-threatening allergic reactions by consuming this product," the notice stated.
"There have been no reports of injury or illness reported to Mondelēz Global LLC to date related to this product, and we are issuing this recall as a precaution," the FDA said.
But folks who have an allergy or severe sensitivity to peanuts run the risk of a serious or life-threatening allergic reaction if they consume any of these products.
The following Ritz cracker sandwich cartons are being recalled:
8-pack RITZ Peanut Butter Cracker Sandwich carton
UPC: 0 44000 88210 5
Best When Used By Dates: Nov. 1-9, 2025
Plant Code: AE (on top of package)
20-pack RITZ Peanut Butter Cracker Sandwich carton
UPC: 0 44000 07584 2
Best When Used By Dates: Nov. 1-9, 2025, and Jan. 2-22, 2026
Plant Code: AE
40-pack RITZ Peanut Butter Cracker Sandwich carton
UPC: 0 44000 07819 5
Best When Used By Dates: Nov. 1-9, 2025, and Jan. 2-22, 2026
Plant Code: AM
20-pack RITZ Filled Cracker Sandwich Variety Pack carton
UPC: 0 44000 08095 2
Best When Used By Dates: Nov. 2-9, 2025
Plant Code: RJ
Photos of the recalled products can be found on the FDA's website.
Anyone with a peanut allergy should not eat these products, even if they appear to be cheese-flavored. Instead, throw them away, health officials urged.
Other Ritz products, including different cracker types or items from Mondelēz Global LLC, are not affected by the recall.
More information
Read the full recall notice and see photos of the recalled products at the U.S. Food and Drug Administration.
Copyright © 2025 HealthDay. All rights reserved.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Miami Herald
3 days ago
- Miami Herald
Guinness launches ice-cold new collaboration with wild partner
One thing beer lovers agree on is that Guinness, or any beer, should always be ice cold. No one wants to crack open a lukewarm beer that's been baking under the sun for hours. But with summer at its peak, keeping beer cold outside can be a serious challenge, so Guinness has joined forces with a surprising partner to launch a new product that will solve this problem. Don't miss the move: Subscribe to TheStreet's free daily newsletter Founded in 1759 in Dublin, Ireland, Guinness is the world's most popular stout. It is known for its dark color and signature creamy texture, which is due to the use of nitrogen in its brewing process. The brand has been owned by the alcoholic beverage company Diageo (DEO) since 1997. Today, it's brewed in 49 countries worldwide and sold in over 150. Related: Guinness parent makes major investment in a surprising market Guinness offers various beer products in multiple presentations, as well as nonalcoholic Guinness 0.0 and cold brew coffee beer. However, unknown to some, it has expanded into the food market with coffee, chocolate, fudge, sauce, and even potato chips. Now, Guinness is taking it a step further by collaborating with a new partner to create a one-of-a-kind product that fuses beer and ice cream. Guinness has teamed up with the ice cream brand Van Leeuwen to launch "Lovely Day for Guinness," a new limited-edition ice cream that blends the flavor of Guinness and mixes it with chocolate chunks. This new flavor's name and packaging design are inspired by a 1950s Guinness advertising campaign, which matches the look of Guinness' new limited-edition summer Draught Stout 4-pack. Related: Taco Bell brings back exclusive menu collaboration for a limited time While the idea of combining beer and ice cream may sound odd to some people, Van Leeuwen is confident that skeptics will love the taste. "It's unexpected in the best way – and we think people are going to be surprised by how naturally Guinness and ice cream go together," said Van Leeuwen CEO Ben Van Leeuwen. The new "Lovely Day for Guinness" is available in 14-ounce pints for $11.15 at Van Leeuwen Scoop Shops nationwide or on its online website for $12 while supplies last. From humble beginnings as an ice cream truck in the streets of New York City in 2008, Van Leeuwen has grown into a massive brand, with multiple scoop shops nationwide and a retail empire of ice cream products spread across various grocery stores and online. Although "Lovely Day for Guinness" may sound like a wild flavor choice, Van Leeuwen is no stranger to pushing the boundaries of ice cream. More Food News: Pepsi and Coca-Cola rival brings SpongeBob to healthy sodaTaco Bell reveals new menu item with dream partnerPapa Johns announces wild new menu deal to win back customers The brand previously created more unusual limited-edition flavors with unexpected partners, including collaborating with Hidden Valley Ranch, Kraft Macaroni & Cheese, Dijon Mustard, and Tapatío Hot Sauce, to name a few. While the new "Lovely Day for Guinness" ice cream contains the signature taste of Guinness, fans can't get boozy off this pint, because it's made with Guinness 0 nonalcoholic beer and contains no alcohol. Related: Veteran fund manager unveils eye-popping S&P 500 forecast The Arena Media Brands, LLC THESTREET is a registered trademark of TheStreet, Inc.
Business Wire
4 days ago
- Business Wire
Aldeyra Therapeutics Receives Orphan Designation from the European Medicines Agency for ADX-2191 for the Treatment of Inherited Retinal Dystrophies including Retinitis Pigmentosa
LEXINGTON, Mass.--(BUSINESS WIRE)-- Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that the European Medicines Agency (EMA) has granted Orphan Designation for ADX-2191 (methotrexate intravitreal injection) for the treatment of inherited retinal dystrophies of the rod-dominant phenotype, including retinitis pigmentosa. There are currently no approved drug treatments for patients with most forms of retinitis pigmentosa, a clinical group of rare genetic eye diseases characterized by retinal cell death and loss of vision. Retinitis pigmentosa affects more than one million people worldwide and remains a significant cause of inherited blindness. 'Retinitis pigmentosa is a serious and incurable sight-threatening disease that represents a major unmet need in the field of ophthalmology,' stated Todd C. Brady, M.D., Ph.D., President and CEO of Aldeyra. 'The receipt of Orphan Designation from the EMA, in conjunction with the previously announced Orphan Drug Designation from the U.S. Food and Drug Administration, highlights the importance of developing a treatment option for patients suffering from retinitis pigmentosa.' The potential activity of ADX-2191 in retinitis pigmentosa is supported by results from a Phase 2 clinical trial, announced in 2023, which demonstrated improvements from baseline in retinal sensitivity following treatment. A planned Phase 2/3 clinical trial of ADX-2191 in retinitis pigmentosa is expected to initiate in 2025. The EMA grants orphan designation to drugs and biologics intended for the treatment, diagnosis, or prevention of rare, life-threatening, or chronically debilitating diseases or conditions that affect fewer than five in 10,000 people in the European Union. Orphan designation allows companies certain benefits, including reduced regulatory fees, clinical protocol assistance, research grants, and up to 10 years of market exclusivity in the European Union. About ADX-2191 ADX-2191 (methotrexate intravitreal injection) is a sterile, non-compounded intravitreal formulation of methotrexate for the potential treatment of specific rare retinal diseases, including primary vitreoretinal lymphoma and retinitis pigmentosa. The ADX-2191 intravitreal formulation is preservative-free, is designed to be vitreous-compatible, and is optimized for excipient composition, viscosity, density, tonicity, pH, concentration, and volume of administration. ADX-2191 has received U.S. Food and Drug Administration (FDA) Orphan Drug Designation for the treatment of primary vitreoretinal lymphoma and retinitis pigmentosa, and EMA Orphan Designation for the treatment of inherited retinal dystrophies of the rod-dominant phenotype, including retinitis pigmentosa. About Retinitis Pigmentosa Retinitis pigmentosa is a group of rare genetic eye diseases characterized by retinal cell death and loss of vision. There are currently no approved treatments for most forms of retinitis pigmentosa. In vivo preclinical research has identified the activity of methotrexate in inducing misfolded rhodopsin (a visual cycle protein) clearance, suggesting the potential of ADX‑2191 to treat genetic forms of retinitis pigmentosa that are characterized by misfolded rhodopsin. About Aldeyra Aldeyra Therapeutics is a biotechnology company devoted to discovering innovative therapies designed to treat immune-mediated and metabolic diseases. Our approach is to develop pharmaceuticals that modulate protein systems, instead of directly inhibiting or activating single protein targets, with the goal of optimizing multiple pathways at once while minimizing toxicity. Our product candidates include RASP (reactive aldehyde species) modulators ADX-629, ADX‑248, ADX-743, ADX-631, ADX-246, and chemically related molecules for the potential treatment of systemic and retinal immune-mediated and metabolic diseases. Our late-stage product candidates are reproxalap, a RASP modulator for the potential treatment of dry eye disease and allergic conjunctivitis, and ADX-2191, a novel formulation of intravitreal methotrexate for the potential treatment of primary vitreoretinal lymphoma and retinitis pigmentosa. Safe Harbor Statement This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding Aldeyra's future expectations, plans, and prospects, including without limitation statements regarding: the goals, opportunity, and potential for ADX-2191; and the outcome and timing of any clinical trials of ADX-2191. Aldeyra intends such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. In some cases, you can identify forward-looking statements by terms such as, but not limited to, 'may,' 'might,' 'will,' 'objective,' 'intend,' 'should,' "could," 'can,' 'would,' 'expect,' 'believe,' 'anticipate,' 'project,' 'on track,' 'scheduled,' 'target,' 'design,' 'estimate,' 'predict,' 'contemplates,' 'likely,' 'potential,' 'continue,' 'ongoing,' 'aim,' 'plan,' or the negative of these terms, and similar expressions intended to identify forward-looking statements. Such forward-looking statements are based upon current expectations that involve risks, changes in circumstances, assumptions, and uncertainties. Aldeyra is at an early stage of development and may not ever have any products that generate significant revenue. All of Aldeyra's development timelines may be subject to adjustment depending on recruitment rate, regulatory review, preclinical and clinical results, funding, and other factors that could delay the initiation, enrollment, or completion of clinical trials. Important factors that could cause actual results to differ materially from those reflected in Aldeyra's forward-looking statements include, among others, the timing of enrollment, commencement and completion of Aldeyra's clinical trials, the timing and success of preclinical studies and clinical trials conducted by Aldeyra and its development partners; delay in or failure to obtain regulatory approval of Aldeyra's product candidates, including as a result of the FDA not accepting Aldeyra's regulatory filings, issuing a complete response letter, or requiring additional clinical trials or data prior to review or approval of such filings or in connection with resubmissions of such filings; the ability to maintain regulatory approval of Aldeyra's product candidates, and the labeling for any approved products; the risk that prior results, such as signals of safety, activity, or durability of effect, observed from preclinical or clinical trials, will not be replicated or will not continue in ongoing or future studies or clinical trials involving Aldeyra's product candidates in clinical trials focused on the same or different indications; the scope, progress, expansion, and costs of developing and commercializing Aldeyra's product candidates; uncertainty as to Aldeyra's ability to commercialize (alone or with others) and obtain reimbursement for Aldeyra's product candidates following regulatory approval, if any; the size and growth of the potential markets and pricing for Aldeyra's product candidates and the ability to serve those markets; Aldeyra's expectations regarding Aldeyra's expenses and future revenue, the timing of future revenue, the sufficiency or use of Aldeyra's cash resources and needs for additional financing; the rate and degree of market acceptance of any of Aldeyra's product candidates; Aldeyra's expectations regarding competition; Aldeyra's anticipated growth strategies; Aldeyra's ability to attract or retain key personnel; Aldeyra's commercialization, marketing and manufacturing capabilities and strategy; Aldeyra's ability to establish and maintain development partnerships; Aldeyra's ability to successfully integrate acquisitions into its business; Aldeyra's expectations regarding federal, state, and foreign regulatory requirements; political, economic, legal, social, and health risks, public health measures, and war or other military actions, that may affect Aldeyra's business or the global economy; regulatory developments in the United States and foreign countries; Aldeyra's ability to obtain and maintain intellectual property protection for its product candidates; the anticipated trends and challenges in Aldeyra's business and the market in which it operates; and other factors that are described in the 'Risk Factors' and 'Management's Discussion and Analysis of Financial Condition and Results of Operations' sections of Aldeyra's Annual Report on Form 10-K for the year ended December 31, 2024, and Aldeyra's Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, which are on file with the Securities and Exchange Commission (SEC) and available on the SEC website at Additional factors may be described in those sections of Aldeyra's Quarterly Report on Form 10-Q for the quarter ended June 30, 2025, expected to be filed with the SEC in the third quarter of 2025, and Aldeyra's other filings with the SEC. In addition to the risks described above and in Aldeyra's other filings with the SEC, other unknown or unpredictable factors also could affect Aldeyra's results. No forward-looking statements can be guaranteed and actual results may differ materially from such statements. The information in this release is provided only as of the date of this release, and Aldeyra undertakes no obligation to update any forward-looking statements contained in this release on account of new information, future events, or otherwise, except as required by law.
New York Post
4 days ago
- New York Post
Inside the ‘arms race' to win the new luxury cruise ship market
Once viewed by wealthier vacationers as mass market, déclassé venues for watery cocktails, garish waterslides, buffet stampedes and Norovirus outbreaks, cruises are now chic. Everyone from Martha Stewart and Tom Brady to Kendall Jenner and Dakota Johnson was onboard the Ritz's recent launch of Luminara, the hotel brand's new ship, which has been floating around the Mediterranean. Savvy investors and luxury brands are recognizing cruises as the next frontier for high-end travel. Advertisement 5 'There is an arms race between high-end hotels to get into the luxury cruise space,' Jim Murren, CEO of The Ritz-Carlton Yacht Collection told me. The Ritz-Carlton Yacht Collection/INSTARimages The billionaire Francois Pinault, whose family has owned French cruise line Ponant for a decade, bought a majority stake in the luxe cruise line Aqua Expeditions earlier this year. Bernard Arnault and LVMH have invested in an Orient Express ship that is currently under construction and set to be delivered next year. Advertisement Following in the Ritz's wake, in 2026, the Waldorf Astoria will wet its feet in the cruise space with a Nile River trip launching, while the Four Seasons will set sail in the Caribbean and Mediterranean. The Aman will hit the high seas with a 50-suite ship in 2027. 'There is an arms race between high-end hotels to get into the luxury cruise space,' Jim Murren, CEO of The Ritz-Carlton Yacht Collection told me. 5 Martha Stewart was one of the celebrity guests on the recent Ritz-Carlton cruise. Martha Stewart/Instagram For the hospitality companies, it's an easy way to enter a new and growing market — luxe cruises are expected to expand from $10.5 billion this year to $19.8 billion by 2033 according to Business Research Insights — while relying on the safety of their existing brand. Advertisement 'If you're a new entrant who has decided to get into a new product, it is far easier with a known branch attached like a luxury hotel — people will pay 15% more if there is a name like Ritz Carlton attached,' Richard Clarke, a senior analyst for global hotels, cruise lines & online travel at Bernstein told me. 'It is a well trodden path to expand beyond your core product and see what else you can do.' Various luxury hotel companies have recently launched high-end clothing lines, bedding collections, and bags, while branded residences have been popular for years. 5 The Aman will hit the high seas with a 50-suite ship in 2027. Aman 'The fact it's all coming at once is proof the concept works … and the high-end consumer has never been more attractive,' Clarke said. Advertisement Unlike mega-cruise ships, which can't reach more intimate ports and can hold more than 4,000 passengers, most of these high-end vessels are nimble enough to reach harder-to-get-to destinations like St. Barth's in the Caribbean or Capri in the Mediterranean. Ritz's new boat, Luminara, accommodates just 452 guests while another of its ships, Evrima, has room for only 298 guests. The Ritz ships include restaurants designed by Michelin-starred chefs, sprawling suites, extensive spas, infinity pools, marinas with water sports galore and art collections that feature works from Andy Warhol, Henri Matisse and Alexander Calder. 5 Billionaire Francois Pinault owns French cruise line Ponant. Ponant Ponant's ships — which have room for fewer than 40 guests — even offer an underwater lounge with ocean views. Ponant is known primarily for exploring far-flung destinations like Antarctica and the North Pole, while Aqua Expeditions goes to remote rivers like the Amazon and Mekong. The upcoming cruises from the Aman, Four Seasons, the Orient Express and Waldorf Astoria will feature sprawling suites and amenities such as a Japanese Zen garden and a jazz club. This story is part of NYNext, an indispensable insider insight into the innovations, moonshots and political chess moves that matter most to NYC's power players (and those who aspire to be). Most of these trips start around $20,000 per week and go up in price from there depending on factors like the size of your room and how much caviar you order. Advertisement While it's not surprising companies would jump on this growing market, it has surprised me how quickly travelers have embraced it. Just why — apart from a barrage of influencers posting about their trips — are these vacations catching on? 5 Jeff Bezos' sailing boat Koru is one of the largest in the world at 417 feet. AbacaPress / Part of it is very careful branding of these cruises. In marketing materials, the vessels are referred to as yachts not cruise ships. Silver-haired retirees have been swapped out for glam influencers, models, and movie stars. Advertisement 'The fact that yachts are splashed across tabloids makes it seem like it is the kind of vacation you should take,' Clarke noted. For multi-millionaires who dream of being billionaires (or at least scoring an invite on one of their yachts), the new upscale cruise is a way to have a private yacht experience without buying one themselves — ala Jeff Bezos or David Geffen — or paying six figures to charter a vessel. They're perfect for the Instagram era where everyone wants to 'show some rail' — a reference to the myriad photos taken in front of the enclosure on the ship. Advertisement 'It's an entirely new category, designed for travelers who seek the privacy and exclusivity of a yacht charter, paired with the elevated service and amenities of a luxury resort-at-sea,' Murren said. Send NYNext a tip: NYNextLydia@
